Northern Trust Corp Purchases 43,032 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

Northern Trust Corp increased its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 467,179 shares of the company's stock after purchasing an additional 43,032 shares during the quarter. Northern Trust Corp owned about 0.83% of Astrana Health worth $14,730,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health during the third quarter worth $13,383,000. Franklin Resources Inc. acquired a new position in Astrana Health in the 3rd quarter valued at about $1,187,000. Barclays PLC bought a new stake in Astrana Health in the 3rd quarter valued at about $4,457,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Astrana Health by 348.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,788 shares of the company's stock worth $1,191,000 after acquiring an additional 29,355 shares during the period. Finally, Truist Financial Corp bought a new position in Astrana Health in the 4th quarter valued at approximately $315,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on ASTH. Barclays started coverage on shares of Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price objective for the company. Truist Financial cut their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Bank of America lowered their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Finally, Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.29.

Astrana Health Price Performance

ASTH stock opened at $27.06 on Friday. The company has a fifty day simple moving average of $30.82 and a two-hundred day simple moving average of $35.62. The firm has a market capitalization of $1.52 billion, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 1.37 and a beta of 1.00. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a 52 week low of $23.12 and a 52 week high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $620.39 million for the quarter, compared to analysts' expectations of $628.11 million. During the same period last year, the business posted $0.31 EPS. The company's revenue for the quarter was up 53.4% on a year-over-year basis. Analysts anticipate that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.